Scientists talked about the role of two bacteria in intestinal inflammation
Scientists from Germany and Canada have discovered two types of intestinal bacteria that increased inflammation in experiments. In the mouse experiment, suppression of one of these species helped reduce inflammation. About how scientists have determined the role of individual bacteria and what this can change in the treatment of Crohn's disease and ulcerative colitis, in the Izvestia article.
How are the microbiota and intestinal inflammation related?
With inflammation, the composition of the intestinal microbiota changes — the community of microorganisms that live in the intestine. Some species can reproduce more actively in these conditions. Some of them are able, in turn, to support the inflammatory response.
Crohn's disease and ulcerative colitis are both chronic inflammatory bowel diseases (IBD). In Crohn's disease, inflammation can affect any part of the digestive tract. Ulcerative colitis affects the colon mucosa. Common symptoms include abdominal pain and diarrhea. In both diseases, periods of exacerbation can be followed by remission.
Why was the patient's microbiota transferred to mice
A team led by Lukas Mager from the University Hospital of Tubingen and University of Calgary professor Katie McCoy compared stool samples collected from patients before and after taking antibiotics or fecal microbiota transplantation. In such a transplant, the intestinal microorganisms of the donor are transferred to a person. Since the composition of the microbiota varies greatly from person to person, comparing samples from one patient made it possible to track what changed after the intervention.
Microorganisms from the samples were transferred to mice grown without their own microbiota, and the inflammation was observed to change. In one of the models, mice had a deficiency of mucin MUC2, the main protein of the protective mucus of the colon. The inner layer of this mucus normally separates bacteria from the cells lining the intestine.
For the next stage, the scientists selected the bacteria based on how they bound to the antibodies. Then the effect of these species on inflammation was tested separately.
Which bacteria increased the inflammation
In experiments, two species, Sarcina perfringens and Hathewaya massiliensis, activated cells of the innate immune system and enhanced the inflammatory response. The scientists also tested the bacteria on intestinal organoids, miniature models of tissues grown from human cells. Experiments have shown that bacteria can disrupt the epithelium that lines the intestine from the inside.
The researchers then found out how often elevated levels of these bacteria occur in people with IBD. In international samples, this indicator was about 25-30% for Sarcina perfringens and about 5% for Hathewaya massiliensis.
"In inflammatory bowel diseases, the provoking factors may vary from patient to patient," explained Mager.
According to him, the search for bacteria involved in inflammation in a particular person can help in the development of personalized treatment.
How scientists searched for a substance with selective action
Some intestinal bacteria process dietary fiber and produce butyrate, which serves as an energy source for colon cells. To preserve such functions of the microbiota, scientists were looking for a substance that suppresses individual species and affects the rest of the bacterial community as little as possible.
Of the 1,518 previously approved compounds, the researchers selected five. In experiments, they suppressed the growth of target bacteria and had little effect on other common species.
Oxolic acid was tested on mice in which inflammation was increased by Sarcina perfringens. In reducing inflammation, its effect was comparable to that of metronidazole, a broad-spectrum antibiotic. At the same time, oxolic acid had a weaker effect on the remaining bacteria that were monitored in the experiment.
What needs to be checked in patients
Treatment of Crohn's disease and ulcerative colitis is aimed at reducing inflammation and maintaining remission. For this purpose, biological drugs are used, in particular, which act on individual links of the immune response. If it can be confirmed that a certain bacterium supports inflammation in a particular person, exposure to it can complement this therapy.
Doctors are already using stool analysis to assess IBD activity. For example, the level of fecal calprotectin helps to judge inflammation, including when symptoms have subsided. To select a treatment based on the microbiota, it will be necessary to establish by what signs it is possible to identify a patient in whom suppression of a particular bacterium can have an effect.
Clinical studies will have to test how safe it is to selectively suppress these bacteria in humans and whether this approach helps reduce inflammation and prolong remission.
Переведено сервисом «Яндекс Переводчик»